Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center
IntroductionFingolimod (Fg), a sphingosine 1-phosphate receptor modulator, decreases the annual relapse rate (ARR) in relapsing-remitting multiple sclerosis (RRMS). The aim of this study was to assess the efficacy and safety of Fg in daily practice in patients with RRMS, previously treated with nata...
Main Authors: | Thomas Roux, Elisabeth Maillart, Jean-Sébastien Vidal, Sophie Tezenas du Montcel, Catherine Lubetzki, Caroline Papeix |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-05-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fneur.2017.00183/full |
Similar Items
-
Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01) -
Fingolimod (FTY720) Tedavisinin Relapsing-Remitting Multipl Skleroz Hastalarında Karaciğer Enzim Düzeylerine Etkisi
by: Duygu Tap, et al.
Published: (2020-12-01) -
Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
by: Marina Boziki, et al.
Published: (2021-08-01) -
Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Xin Wu, et al.
Published: (2021-05-01) -
Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis
by: Heather Gwen Mack, et al.
Published: (2016-12-01)